Kornimate/medical-research-clean huggingface dataset:
diagnostic performance of an antigen test for sars-cov-2 infection (covid-19)

Conditions: Covid-19

Summary: a comparison of a direct antigen test for sars-cov-2 obtained by mid-turbinate swab with the reference standard rt-pcr test obtained by nasopharyngeal swab in outpatients with symptoms compatible with covid-19.

this study plans to compare a direct antigen test for severe acute respiratory syndrome coronavirus 2 (sars-cov2) obtained by mid-turbinate nasal swab with a reverse transcription polymerase chain reaction (rt-pcr) test obtained by nasopharyngeal swab (the current reference standard) in a population of patients with symptoms suggestive of covid-19 for fewer than 5 days. subjects whose physicians have already ordered an rt-pcr test at a carilion testing center will be screened and recruited by phone during a required scheduling call. the study coordinator will describe the study by phone, and the subject will be consented when they arrive at the testing center. after consenting, a mid-turbinate swab direct antigen test will be obtained just prior to the ordered nasopharyngeal swab and any other ordered tests. the subjects will receive their rt-pcr test results through the usual channels of clinical notification. the subjects will not receive their nasal antigen results. the antigen test results will be analyzed in a batch process and the results entered into redcap by the study staff. the rt-pcr results will be extracted from the epic electronic health record using patient identifiers and paired with the corresponding antigen result for statistical analysis.

Eligibility criteria:
inclusion criteria: * acutely ill with one or more covid-19 symptoms exclusion criteria: * unable to speak english * unable to provide written informed consent * symptoms have lasted longer than 5 days * currently hospitalized

Keywords: diagnostic test antigen test pcr test symptomatic
in vivo damage induced bu uv in the epidermis of the scalp

Conditions: Squamous Cell Carcinomas

Summary: squamous cell carcinomas (scc) are the second most common skin cancer in humans. the incidence of sccs in the usa in 2012 was estimated at 700,000 casessccs have a metastatic course in 3% to 5% of cases that is of poor prognosis. in men, the sccs of the scalp represent the most frequent location of the head and neck, the 3rd location of the whole body. the sccs of the scalp are more undifferentiated than in other locations. in addition, actinic keratoses of scalp, precursors of scc, are more resistant to treatment than in other areas. these particularities of the sccs of the scalp suggest the existence of specific factors at the epidermis level of the scalp. uv-induced damage to dna is the defining event in skin photocarcinogenesis. it has already been shown that dna damage induced by uv and the kinetics of repair of this damage may vary with age or phototype of patients, but the topographic variation of dna damage has never been studied, although it is known that gene expression in skin cells may differ from one region of the body to another. the hypothesis is therefore that the particular characteristics of kas and sccs at the scal level could be explained by an increased sensitivity to uv-induced damage. it is planned to study uv-induced damage and its repair at the scalp level in humans compared to the forearm.


Eligibility criteria:
inclusion criteria: * male subject * subject aged 40 to 60 years * subject of phototype iii or iv * subject with no skin lesions on the scalp and forearms * subject who has not been exposed to the sun for at least 1 month * subject affiliated to social security * subject who signed the informed consent form exclusion criteria: * subjects with photosensitivity, * subject taking photosensitizing drugs * subjects with a history of skin cancer * subjects with abnormal healing * subjects with immunosuppression
evaluation of igy antibody efficacy in egg yolk against helicobacter pylori in bacterial elimination and clinical symptoms improvement of gastrointestinal patients

Conditions: HELICOBACTER PYLORI INFECTIONS; Gastrointestinal Disease

Summary: 1. investigating its effectiveness in removing bacteria in invivo conditions 2. investigating the effectiveness in improving the clinical symptoms of patients


Eligibility criteria:
inclusion criteria: * patients with gastritis or stomach ulcers whose helicobacter infection has been confirmed by a doctor and age group 18 to 78 years, all genders, if accepted exclusion criteria: * acute perforation of esophagus, stomach and duodenum hyperlipidemic people those who are allergic to egg proteins patients with stomach cancer

Keywords: igy helicobacter pylori clinical trial antibody gastrointestinal disease
nmda enhancement combined with omega-3 for early dementia

Conditions: Omega 3 Fatty Acids; Dementia

Summary: in this 4-year proposed project, we will enroll 140 patients with amci or mild ad into a 24-week randomized, double-blind, placebo-controlled drug trial. all patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: \[1\] daoib + omega-3; \[2\] daoib + placebo. we will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). we hypothesize that daoib combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with amci or mild ad.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of alzheimer's disease or mild cognitive impairment * mmse between 10-26 * cdr 1 or 0.5 exclusion criteria: * hachinski ischemic score \> 4 * substance abuse/dependence * parkinson disease, epilepsy, dementia with psychotic features * major depressive disorder * major physical illnesses * memantine or special omega-3 fatty acids therapy within 3 months before enrollment * severe visual or hearing impairment
safety and immunogenicity of a single dose of intranasal seasonal trivalent live-attenuated influenza vaccine

Conditions: Influenza

Summary: in this phase ii randomized controlled clinical trial, generally healthy male and female children from 24 through 59 months of age will be enrolled in kamalapur (dhaka), bangladesh. the study is expected to continue for at least 6 months following vaccination. the experimental intervention is serum institute of india ltd's trivalent, seasonal live attenuated influenza vaccine (siil laiv). the study vaccine has been formulated according to who recommendations for the 2011-2012 northern hemisphere influenza season. the siil laiv is administered in a 0.5 ml intranasal dose (one spray of 0.25 ml per nostril) via a reusable sprayer device and a single-use nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx. the comparator vaccine will be an inactive placebo identical in appearance to the active vaccine. the primary study hypothesis is that laiv is safe and well tolerated by children aged 24 through 59 months in bangladesh. a secondary hypothesis is that laiv is immunogenic among children receiving study vaccine as compared to children receiving placebo.


Eligibility criteria:
inclusion criteria: * healthy male or female child at least 24 months of age and no older than 59 months of age at the time of study vaccination * a child whose parent or guardian's primary residence, at the time of study vaccinations, is within the kamalapur surveillance site catchment area and who intends to be present in the area for the duration of the trial * a child whose parent or legal guardian is willing to provide written informed consent prior to the participant's study vaccination exclusion criteria: * has any serious chronic disease including progressive neurologic disease, tuberculosis, down's syndrome or other cytogenetic disorder, or known or suspected disease of the immune system * is receiving immunosuppressive agents including systemic corticosteroids during the two weeks prior to study vaccination * has a history of documented hypersensitivity to eggs or other components of the vaccine (including gelatin, sorbitol, lactalbumin and chicken protein), or with life-threatening reactions to previous influenza vaccinations * is receiving aspirin therapy or aspirin-containing therapy currently or two weeks before * lives in household with somebody currently participating in a respiratory vaccination or antiviral study * has current or past participation (within 2 months of trial enrollment visit) in any clinical trial involving a drug or biologic with activity against respiratory disease * has any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential health risk to the child

Keywords: influenza vaccines influenza, human live attenuated influenza vaccine
analysis of the relationship between the quantitative index of cytokines in the oral fluid and inflammation

Conditions: Chronic Inflammation

Summary: the of study is to increase the effectiveness of orthopedic rehabilitation of patients with postoperative jaw defects using various types of replacement structures, taking into account the clinical and morphofunctional characteristics of oral tissues after surgery.

formation of three groups of patients patients with extensive jaw defects after surgery for oncological disease of the middle zone of the face (10 people) patients with jaw defects after complicated tooth extraction (20 people) healthy volunteers to determine reference values (5 people) data on the functional state of the dentoalveolar system in the study groups of patients will be obtained. an assessment will be made of the rate of formation of a postoperative defect in patients with postoperative jaw defects, depending on the design features of the prosthesis. defects of the jaw will be replaced with orthopedic structures, taking into account the individual characteristics of the state of the marginal part of the defect. data will be obtained on the rate of adaptation and quality of life in patients using dentures made taking into account the assessment of the state of the marginal part of the defect. clinical recommendations for dentists will be proposed, which will optimize the process of orthopedic dental treatment, taking into account the state of the marginal part of the defect in patients with postoperative jaw defects.

Eligibility criteria:
inclusion criteria: * men or women over 30 years of age. the presence of a postoperative defect of the jaw after surgical interventions. exclusion criteria: * men or women under 30 years of age. decompensated somatic pathology. pregnancy or breastfeeding in women. participation in another study.

Keywords: denture, removable, cytokine, saliva, jaw
evaluation of whether functional strength training can enhance motor recovery of the upper limb after stroke

Conditions: Stroke

Summary: the purpose of this study is to test the hypothesis that adding functional strength training to uk conventional therapy improves muscle function and walking than either uk conventional therapy alone or increased intensity of uk conventional therapy.

neuromuscular weakness occurs frequently after stroke and the processes underlying recovery are still poorly understood. accepted practice in uk physiotherapy is to avoid training of muscle strength after stroke but there is preliminary evidence that it might be effective. an observer-blind randomised pilot clinical trial (phase ii). subjects will be within 3 months of first stroke with some voluntary movement in the paretic upper limb. a research physiotherapist, blinded to measurement, will recruit subjects, allocate subjects to one of three intervention groups using sequentially numbered sealed envelopes containing previously allocated intervention cards and provide interventions. ten participants will be recruited to each group therefore the trial will recuit 30 participants. the research assessor, blinded to intervention allocation will undertake all measurements. conventional therapy (control) will be provided as normal for the clinical setting, the additional conventional therapy (experimental 1)or functional strength training (experimental 2) will be provided for one hour, five times a week for six weeks. subjects in the two experimental groups will also receive the conventional therapy standard in their clinical setting. blinded measurement will be made before randomisation, at the end of intervention and 12-weeks thereafter. primary outcomes are the action research arm test (arat)and the nine hole peg test (9hpt). the secondary outcomes are peak torque around the elbow joint in elbow flexion and extension, grip force, pinch force, smoothness of movement during turning a cranked wheel and reciprocal inniveration of biceps and triceps during turning of a cranked wheel. data will be analysed using descriptive statistics and the estimation of standard deviations will be used to inform a power calculation to estimate sample size for a phase ii randomised controlled trial.

Eligibility criteria:
inclusion criteria: * be between one week and three months after stroke when recruited to the study * have some voluntary muscle activity in the paretic upper limb exclusion criteria: * obvious unilateral visuospatial neglect * upper limb movement deficits attributable to non-stroke pathology

Keywords: stroke rehabilitation physical therapy
the role of circadian rhythms in cancer-related symptoms

Conditions: Breast Cancer; Fatigue; Cognitive Impairment; Sleep; Depression; Quality of Life; Stress, Psychological; Inflammation; Circadian Rhythm Disorders; Cancer-Related Syndrome

Summary: emerging evidence indicates that circadian rhythms may be disrupted following cancer and its treatment, and that circadian rhythm disruption may be an underlying pathophysiological mechanism of cancer- and cancer treatment-related symptoms (crs) such as fatigue, sleep disturbance, cognitive impairment, and depressed mood. given the detrimental effect of crs on cancer survivors' quality of life, and a pressing demand for effective interventions to treat crs, there is a need for a comprehensive examination of circadian disruption related to cancer and its treatment, and its association with crs. the study will prospectively examine circadian rhythms and a crs composite score in recently diagnosed breast cancer patients from prior to surgery or chemotherapy to 12 months later. a matched healthy control group will serve as a comparison.


Eligibility criteria:
inclusion criteria: * patients with early breast cancer scheduled for surgery and chemotherapy (neoadjuvant or adjuvant) at aarhus university hospital (auh). * the healthy control group will consist of an age-matched sample of participants with no history of cancer. exclusion criteria: * pregnancy * shift-work * melatonin supplementation * insufficient danish proficiency * previous cancer diagnosis except for treated non-melanoma skin cancer * confounding diagnosed or suspected psychiatric or medical conditions that might significantly contribute to the crs or symptoms/diagnoses resembling them (other than those caused by cancer or its treatment) such as seasonal affective disorder.

Keywords: breast cancer circadian rhythms disruption cancer-related symptoms
effect of degenerative spondylolisthesis on the clinical outcome of unilateral biportal endoscopy for lumbar spinal stenosis: study protocol

Conditions: Degenerative Spondylolisthesis; Lumbar Spinal Stenosis

Summary: a single-center, prospective cohort trial aims to provide stronger evidence regarding the impact of degenerative spondylolisthesis on the clinical outcome of unilateral biportal endoscopy for lumbar spinal stenosis


Eligibility criteria:
inclusion criteria: * age range: 50-80 years * diagnosis of lss affecting 1-2 vertebral levels * predominant manifestation of neurogenic intermittent claudication, with ineffective conservative treatment for at least 3 months * presence of lumbar ds of less than grade ii and absence of spine instability * willingness to participate in the study and complete follow-up assessments. exclusion criteria: * diagnosis of isthmic lumbar spondylolisthesis or lumbar ds of grade ≥ii * evidence of instability at the affected vertebral level (intervertebral angle change \> 15° and/or vertebral translation ≥ 4.5 mm in standing flexion-extension radiographs of the lumbar spine) * history of prior surgery at the affected vertebral level * presence of scoliosis with a cobb angle \>20º * presence of other conditions affecting the lumbar spine (infection, tumor, fracture, neurological diseases, and others) * medical disorders that preclude surgical tolerance * participation in other clinical research projects related to the treatment of lumbar spinal stenosis.
corrections work's adverse effects and a total worker health program to enhance well-being

Conditions: Occupational Stress; Health Behavior; Safety Issues; Mental Health Wellness 1

Summary: conduct a quasi-experimental pre-post study of a mindfulness-enhanced, web/app-enabled, scalable total worker health (twh) program among higher stress corrections professionals. the primary outcomes relate to behaviors promoted by the program: being mindful/reduced stress/improved mood; healthier eating; more physical activity; greater restorative sleep; improved work-life balance and greater positive feelings about the organization.

this proposed project will assess an innovative, scalable total worker health and wellness intervention among high stress corrections professionals. as stated in the proposal request, organizational and interpersonal factors have been associated with significant stress among corrections professionals, but there is limited assessment of effective and feasible interventions to mitigate these stress factors. our current research has established robust constructs for characteristics of the organization and work environment, noting significant relationships with perceived stress. this critical understanding along with corresponding adverse mental and physical effects informs our proposed intervention to reduce potential stressors, enhance wellbeing, improve work performance, and reduce health care costs. this project will include a prospective interrupted time-series effectiveness trial of a mindfulness-enhanced, website/application-based, scalable total worker health (twh) program among higher risk corrections personnel working in restrictive housing units. quantitative outcomes will include process measures; validated self-report indices of primary and secondary outcomes, and proximal potentially mediating factors; anthropometrics; laboratory studies of inflammation, vascular reactivity, and cellular aging; measures of job performance and health care costs. qualitative measures will provide a deeper understanding of the quantitative findings. at program conclusion, there will be a cost effective easy to use work based health and wellness program tailored to corrections departments ready for dissemination. the robust dissemination plan includes coordinating the website and digital materials with the american correctional association marketing and media campaign site along with presentations at national corrections conferences making this freely available to all law enforcement and corrections personnel and agencies.

Eligibility criteria:
inclusion criteria: - currently employed as a corrections professional at participating oregon department of corrections facilities (coffee creek correctional facility and oregon state correctional institution) for at least one month exclusion criteria: - those who are not employed with participating oregon department of corrections facilities listed above.

Keywords: health promotion mindfulness occupational health total worker health safety
defining 'normal' liver function tests & fibroscan values in pregnancy

Conditions: Pregnancy Disease; Liver Diseases

Summary: the main aim of this single-site prospective study is to use serum liver function tests and fibroscan as assessment tools to measure liver disease in pregnant women with or without liver disease at king's college hospital. this will be assessed during each trimester of pregnancy. fibroscan will assess liver stiffness in these participants and will be used as a surrogate marker for fibrosis.

approximately 500 pregnant participants above the age of 16 years will be enrolled into this study, which will occur over an 18-month period (february 2019 to august 2020). in this prospective cohort study, pregnant participants with or without liver disease will be identified through clinics at king's college hospital. participants attending the antenatal, specialist liver-pregnancy clinic and general liver clinics will be given an information leaflet detailing the study. participants can be interviewed in a clinic room to answer any queries. the participant is then given the option of consenting and participating in the study during that clinic consultation or to contact us at a future date should they need further time for consideration. baseline participant details will be collected as well as any preceding liver diagnosis and other comorbidities. once consented, the assessment visits will be as follows. 1. trimester 1 visit (at week 12 booking ultrasound scan): - additional fibroscan after booking scan (ideally 3 hours \*fasting will be required before this scan) 2. trimester 2 visit (at week 20 routine ultrasound scan): * additional fibroscan after ultrasound scan (ideally 3 hours \*fasting will be required before this scan) * blood tests to be taken at this point 3. trimester 3 visit (if occurs, e.g. in participants with diabetes): * fibroscan (ideally 3 hours \*fasting will be required before this scan) * blood tests (liver function tests) 4. post-partum visit (if occurs): * fibroscan (ideally 3 hours \*fasting will be required before this scan) * blood tests (liver function tests) * fasting = nothing to eat or drink (except water) the participants will be followed up during pregnancy and, if required, for 3 months after pregnancy, as per routine obstetric care. delivery, maternal and foetal outcomes will also be documented. this information will come from the participant online medical records.

Eligibility criteria:
inclusion criteria: * must be female * must be aged 16 years and above and be of childbearing age * must be participants attending clinic at king's college hospital * must be in the 1st and 2nd trimester of a pregnancy * must be willing and able to provide written informed consent exclusion criteria: * non-viable pregnancy * pacemaker in situ * concurrent and/or recent involvement in other research that is likely to interfere with fibroscan results within last 3 months of study enrolment

Keywords: fibrosis, fibroscan, pregnancy, trimesters, liver disease